Bavarian Nordic is developing IMVAMUNE, which is based on a live attenuated 
modified vaccinia Ankara virus, for the potential prevention of smallpox 
infection, particularly in those patients contraindicated to traditional 
smallpox vaccines, such as the immunocompromised and those with eczema or 
dermatitis. In phase I and II clinical trials, IMVAMUNE was highly immunogenic 
and safe with no unexpected side effects or serious adverse effects reported in 
either healthy volunteers, those immunocompromised by HIV infection or in 
volunteers with atopic dermatitis. Additional phase II trials were ongoing in 
these groups at the time of publication and phase III trials were planned for 
2009.